NeuroMetrix Skyrockets Ahead Of SENSUS Scheduled Update (NASDAQ:NURO)

NeuroMetrix Inc. (NASDAQ:NURO)

As the global market concerning diabetes presently stands around $41 billion and is predicted to grow over $114 billion in the next year, I would like for you to take a look at NeuroMetrix stock symbol NURO. NeuroMetrix specializes in medical devices for purposes of  treating and managing the neurological complications of diabetes. The Company is currently experiencing a surge of +17.38% Up 0.37 with over 3.5 million shares in play at a price per share value of $2.50 November Wednesday 13, 2013 3:07PM EST. So why is this Company up in today’s stock market you ask. The answer is SENSUS.

SENSUS is a pain management system concerning  the relief of chronic intractable pain and pain relations with diabetic neuropathy. President and Chief Executive Officer of  NeuroMetrix Dr Shai N. Gozani M.D., Ph.D. is expected to provide a update concerning SENSUS in New York, NY November 14, 2013. Read article and disclaimer at http://crwepicks.com/21482/stck-alerts/neurometrix-skyrockets-ahead-of-sensus-scheduled-update-nasdaqnuro/

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crwepicks.com/disclaimer/